Mandate

Vinge advises Investor in connection with Swedish Orphan Biovitrum’s rights issue

April 01, 2011

Vinge is advising Investor AB in connection with Swedish Orphan Biovitrum AB’s (SOBI) rights issue for a total of approximately SEK 600 million subject to pre-emption rights of the existing shareholders. SOBI is listed on NASDAQ OMX Stockholm. Investor AB and Bo Jesper Hansen (SOBI’s chairman) have undertaken to subscribe for their share of the rights issue and the issue has been underwritten by Carnegie and Handelsbanken. As a consequence thereof, Investor has obtained the requisite dispensation from the Swedish Securities Council.

Vinge’s team advising Investor consists of Olle Sandersson, Pontus Enquist and Jesper Schönbeck.

Related

Vinge has advised Consolid on the establishment of Consolid Equity III

The fund held its final closing on June 2, 2025, having secured commitments from a diverse investor base that includes several leading institutional investors from Europe and North America, as well as established fund-of-funds. The fundraising was highly successful, with the fund significantly oversubscribed. Consolid Equity III has more than doubled its total commitments compared to its predecessor fund.
July 02, 2025

Vinge advises EQT VIII in connection with the divestment of Recover to Pangea AS

Recover is a leading Scandinavian property remediation specialist. Following EQT’s acquisition in 2020, Recover has invested in its digital capabilities while divesting non-core business units to sharpen focus on water, fire and other core property remediation services.
July 02, 2025

Vinge advises XPartners on its issuance of senior secured bonds

Vinge advises XPartners Samhällsbyggnad AB (“XPartners”) in connection with its SEK 3 billion issuance of senior secured bonds
July 02, 2025